<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>

<channel>
	<title>Hayes &#187; Health Technology Assessment &#038; Consulting</title>
	<atom:link href="http://www.hayesinc.com/hayes/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.hayesinc.com/hayes</link>
	<description>Transforming Healthcare with Evidence</description>
	<pubDate>Tue, 16 Mar 2010 04:49:34 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.5.1</generator>
	<language>en</language>
			<item>
		<title>Reduced Effectiveness of Plavix in Patients Who Are Poor Metabolizers</title>
		<link>http://www.hayesinc.com/hayes/2010/03/15/reduced-effectiveness-of-plavix-in-patients-who-are-poor-metabolizers/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/15/reduced-effectiveness-of-plavix-in-patients-who-are-poor-metabolizers/#comments</comments>
		<pubDate>Mon, 15 Mar 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/03/15/reduced-effectiveness-of-plavix-in-patients-who-are-poor-metabolizers/</guid>
		<description><![CDATA[

			
				The Food and Drug Administration (FDA) has added a “black box” warning to the label for Plavix® (clopidogrel), an anticlotting medication. The warning relates to patients who do not effectively metabolize the drug (i.e., &#8220;poor metabolizers&#8221;) and, therefore, may not receive the full benefits of the drug. 
			

Plavix is prescribed to reduce the risk of [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/15/reduced-effectiveness-of-plavix-in-patients-who-are-poor-metabolizers/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Spring Managed Care Forum 2010</title>
		<link>http://www.hayesinc.com/hayes/2010/03/11/spring-managed-care-forum-2010/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/11/spring-managed-care-forum-2010/#comments</comments>
		<pubDate>Thu, 11 Mar 2010 13:58:47 +0000</pubDate>
		<dc:creator>kim</dc:creator>
		
		<category><![CDATA[Upcoming Events]]></category>

		<category><![CDATA[What's New]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/?p=962</guid>
		<description><![CDATA[April 22-23, 2010
Walt Disney World&#8217;s Swan and Dolphin
Lake Buena Vista, FL
Hayes will be attending the Spring Managed Care Forum and exhibiting in booth #402.  Contact us to set up an appointment or stop by to learn more about evidence-based analyses to support development of defensible, transparent coverage policies, care management protocols, and best practice guidelines.
]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/11/spring-managed-care-forum-2010/feed/</wfw:commentRss>
		</item>
		<item>
		<title>FDA Reviews the Association of Oral Bisphosphonates to Femoral Fractures</title>
		<link>http://www.hayesinc.com/hayes/2010/03/11/fda-reviews-the-association-of-oral-bisphosphonates-to-femoral-fractures/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/11/fda-reviews-the-association-of-oral-bisphosphonates-to-femoral-fractures/#comments</comments>
		<pubDate>Thu, 11 Mar 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/03/11/fda-reviews-the-association-of-oral-bisphosphonates-to-femoral-fractures/</guid>
		<description><![CDATA[

			
				Recent news reports have raised questions regarding a possible association between oral bisphosphonates and atypical fractures in the bone just below the hip joint. Oral bisphosphonates are commonly prescribed to prevent or treat osteoporosis in postmenopausal women. Common brand names of medications in this class include Fosamax®, Actonel®, Boniva®, and Reclast®.
			

To formally address the issue, [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/11/fda-reviews-the-association-of-oral-bisphosphonates-to-femoral-fractures/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Exercise May Relieve the Anxiety of Chronic Disease</title>
		<link>http://www.hayesinc.com/hayes/2010/03/10/exercise-may-relieve-the-anxiety-of-chronic-disease/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/10/exercise-may-relieve-the-anxiety-of-chronic-disease/#comments</comments>
		<pubDate>Wed, 10 Mar 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/03/10/exercise-may-relieve-the-anxiety-of-chronic-disease/</guid>
		<description><![CDATA[

			
				According to a systematic review published in the Archives of Internal Medicine, exercise training in sedentary patients with chronic conditions may significantly reduce their anxiety, regardless of whether the exercise was classified as moderate or vigorous.  
			


			
				
			A team of Georgia-based researchers reviewed 40 studies done between 1997 and 2005 that measured anxiety at baseline [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/10/exercise-may-relieve-the-anxiety-of-chronic-disease/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Name Change Approved for Kapidex™</title>
		<link>http://www.hayesinc.com/hayes/2010/03/09/name-change-approved-for-kapidex%e2%84%a2/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/09/name-change-approved-for-kapidex%e2%84%a2/#comments</comments>
		<pubDate>Tue, 09 Mar 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/03/09/name-change-approved-for-kapidex%e2%84%a2/</guid>
		<description><![CDATA[

			
				The Food and Drug Administration (FDA) has approved a name change for the heartburn drug Kapidex (dexlansoprazole) to avoid confusion with two other medications—Casodex and Kadian. Effective in late April 2010, Takeda Pharmaceuticals North America Inc. will market Kapidex under the new name Dexilant™.
			

Since Kapidex was approved in January 2009, there have been reports of [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/09/name-change-approved-for-kapidex%e2%84%a2/feed/</wfw:commentRss>
		</item>
		<item>
		<title>New WHI Analysis Finds No Cardioprotective Effect In Postmenopausal Women During First 6 Years of Combination Hormone Therapy</title>
		<link>http://www.hayesinc.com/hayes/2010/03/08/new-whi-analysis-finds-no-cardioprotective-effect-in-postmenopausal-women-during-first-6-years-of-combination-hormone-therapy/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/08/new-whi-analysis-finds-no-cardioprotective-effect-in-postmenopausal-women-during-first-6-years-of-combination-hormone-therapy/#comments</comments>
		<pubDate>Mon, 08 Mar 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/03/08/new-whi-analysis-finds-no-cardioprotective-effect-in-postmenopausal-women-during-first-6-years-of-combination-hormone-therapy/</guid>
		<description><![CDATA[

			
				A retrospective analysis of data from the Women&#8217;s Health Initiative (WHI) published in the Annals of Internal Medicine suggests that combination hormone therapy (HT) increases risk for coronary heart disease (CHD) in healthy postmenopausal women during the first 2 years of use and offers no cardioprotection during the first 8 years of use. The increased [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/08/new-whi-analysis-finds-no-cardioprotective-effect-in-postmenopausal-women-during-first-6-years-of-combination-hormone-therapy/feed/</wfw:commentRss>
		</item>
		<item>
		<title>FDA Announces Class I Recall of Home Dialysis Systems</title>
		<link>http://www.hayesinc.com/hayes/2010/03/05/fda-announces-class-i-recall-of-home-dialysis-systems/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/05/fda-announces-class-i-recall-of-home-dialysis-systems/#comments</comments>
		<pubDate>Fri, 05 Mar 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/03/05/fda-announces-class-i-recall-of-home-dialysis-systems/</guid>
		<description><![CDATA[

			
				The Food and Drug Administration (FDA) and Baxter Healthcare, the manufacturer of the HomeChoice and HomeChoice PRO dialysis systems, have notified patients of a Class I device recall after a number of reported injuries and one death. Recalls receive Class I status when there is reasonable probability that a device or drug will cause serious [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/05/fda-announces-class-i-recall-of-home-dialysis-systems/feed/</wfw:commentRss>
		</item>
		<item>
		<title>American Cancer Society Publishes New Guidelines for Prostate Cancer Screening</title>
		<link>http://www.hayesinc.com/hayes/2010/03/04/american-cancer-society-publishes-new-guidelines-for-prostate-cancer-screening/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/04/american-cancer-society-publishes-new-guidelines-for-prostate-cancer-screening/#comments</comments>
		<pubDate>Thu, 04 Mar 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/03/04/american-cancer-society-publishes-new-guidelines-for-prostate-cancer-screening/</guid>
		<description><![CDATA[

			
				According to newly revised guidelines from the American Cancer Society (ACS), men should discuss the benefits and risks of prostate cancer screening with their doctors. While this is not a radical change from the previous recommendations, the new guidelines offer clearer guidance on what should be discussed. The revised recommendations, last updated in 2006, are [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/04/american-cancer-society-publishes-new-guidelines-for-prostate-cancer-screening/feed/</wfw:commentRss>
		</item>
		<item>
		<title>FDA Approves Prevnar 13 for Infants and Young Children</title>
		<link>http://www.hayesinc.com/hayes/2010/03/03/fda-approves-prevnar-13-for-infants-and-young-children/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/03/fda-approves-prevnar-13-for-infants-and-young-children/#comments</comments>
		<pubDate>Wed, 03 Mar 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/03/03/fda-approves-prevnar-13-for-infants-and-young-children/</guid>
		<description><![CDATA[

			
				The Food and Drug Administration (FDA) has approved Prevnar 13™, a pneumococcal 13-valent conjugate vaccine, for infants and young children ages 6 weeks through 5 years. 
			

Prevnar 13 is the successor to Prevnar®, the pneumococcal 7-valent conjugate vaccine licensed by the FDA in 2000 to prevent invasive pneumococcal disease (IPD) and otitis media. The new [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/03/fda-approves-prevnar-13-for-infants-and-young-children/feed/</wfw:commentRss>
		</item>
		<item>
		<title>HHS Expands Opportunities for Consumers to Record Personalized Health Records</title>
		<link>http://www.hayesinc.com/hayes/2010/03/02/hhs-expands-opportunities-for-consumers-to-record-personalized-health-records/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/02/hhs-expands-opportunities-for-consumers-to-record-personalized-health-records/#comments</comments>
		<pubDate>Tue, 02 Mar 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/03/02/hhs-expands-opportunities-for-consumers-to-record-personalized-health-records/</guid>
		<description><![CDATA[

			
				The office of the U.S. Surgeon General has announced a collaboration with Microsoft® HealthVault™ that will provide new features and expand access to My Family Health Portrait, a free Internet-based resource.
			


			
				
			My Family Health Portrait, a collaborative initiative supported by agencies of the Department of Health and Human Services (HHS), allows users to assemble their family [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/02/hhs-expands-opportunities-for-consumers-to-record-personalized-health-records/feed/</wfw:commentRss>
		</item>
	</channel>
</rss>
